Alzheimer's 'wonder drug' rejected by EU due to side effects risk

Daily Express|July 27, 2024

A DEMENTIA "wonder drug" shown to slow the progress of Alzheimer's has been rejected by the EU regulator.

- Stephen Beech

Alzheimer's 'wonder drug' rejected by EU due to side effects risk

The European Medicines Agency said the side-effect risks of taking lecanemab particularly potentially lethal brain swelling outweigh its impact on slowing cognitive decline.

The drug, known under brand name Leqembi and awaiting approval in the UK, has already been given the green light in both the US and Japan.

But the EMA verdict is being seen as a setback to dementia patients and relatives in Britain.

Some experts believe that additional wealthy patients may now go to the US for the pioneering treatment.

A million people in the UK live with the condition - a total expected to rise to around 1.7 million by 2040.

Risk

Last year dementia killed 66,000 people in England and Wales and it is the leading cause of death in Britain.

Alzheimer's accounts for two-thirds of cases.

هذه القصة مأخوذة من طبعة July 27, 2024 من Daily Express.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

بالفعل مشترك ? تسجيل الدخول

هذه القصة مأخوذة من طبعة July 27, 2024 من Daily Express.

بالفعل مشترك? تسجيل الدخول

المزيد من القصص من DAILY EXPRESS مشاهدة الكل

Daily Express

I REMEMBER THINKING "WHERE ARE MY LEGS?'

Double amputee Martine Wright was the worst injured female survivor of the 7/7 London terror atrocities. Ahead of this year's 20th anniversary, she reveals why she chose happiness over hate through campaigning, motherhood and building a sense of purpose